Sign In
Buy MYOV
$26.98
+0 (+0%)
At Close: Jun 08, 2023
•LIBERTY 1 and LIBERTY 2 achieved 73.4% and 71.2% response rates in menstrual blood loss, with an average reduction of 84.3% from baseline •Achieved six of seven key secondary endpoints including
BASEL, Switzerland and NEW YORK, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced publication in the New England Journal of Medicine of th
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
08:30am, Wednesday, 17'th Feb 2021
BASEL, Switzerland, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it approved equity awa
HealthyWomen and Myovant Sciences Launch “Voices of Periods” to Fight Menstrual Stigma
08:32am, Tuesday, 16'th Feb 2021
RED BANK, N.J. and BASEL, Switzerland, Feb. 16, 2021 (GLOBE NEWSWIRE) -- HealthyWomen, the nation's leading independent, nonprofit health information source for women, and Myovant Sciences (NYSE: MYO
Myovant Sciences Ltd. (MYOV) CEO Dave Marek on Q3 2020 Results - Earnings Call Transcript
03:21pm, Thursday, 11'th Feb 2021
Myovant Sciences Ltd. (MYOV) CEO Dave Marek on Q3 2020 Results - Earnings Call Transcript
Myovant Sciences: Q3 Earnings Insights
09:53am, Thursday, 11'th Feb 2021
Shares of Myovant Sciences (NYSE:MYOV) moved higher by 0.3% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 9.89% year over year to ($0.82), w
Myovant Sciences (MYOV) Reports Q3 Loss, Tops Revenue Estimates
09:04am, Thursday, 11'th Feb 2021
Myovant Sciences (MYOV) delivered earnings and revenue surprises of 7.87% and 27.69%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Myovant Sciences Announces Corporate Updates and Financial Results for Third Quarter of Fiscal Year 2020
06:55am, Thursday, 11'th Feb 2021
BASEL, Switzerland, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced corporate updates and finan
Myovant Sciences to Host Third Fiscal Quarter 2020 Earnings Conference Call at 8:30 a.m. Eastern Time on February 11, 2021
08:30am, Friday, 29'th Jan 2021
BASEL, Switzerland, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and
BASEL, Switzerland and NEW YORK, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the Phase 3 SPIRIT long-term extension study of the i
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
08:30am, Wednesday, 20'th Jan 2021
BASEL, Switzerland, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it approved equity awa
Citigroup, Goldman Sachs, JPMorgan, Tesla and More Wednesday Afternoon Analyst Calls
12:16pm, Wednesday, 06'th Jan 2021
Over halfway through the trading day on Wednesday, and the broad markets are making a run into the afternoon.
CORRECTION -- Myovant Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference
02:57pm, Tuesday, 05'th Jan 2021
BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Myovant Sciences (NYSE: MYOV), please note that in the first paragraph of the release
Myovant Sciences Announces U.S. Availability of ORGOVYX™ for the Treatment of Advanced Prostate Cancer
06:58am, Tuesday, 05'th Jan 2021
BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that ORGOVYX™ (relugolix)
SUMITOVANT BIOPHARMA ANNOUNCES THE APPOINTMENT OF INDUSTRY VETERAN, DAVID MAREK, AS CHIEF EXECUTIVE OFFICER OF MYOVANT SCIENCES
07:10am, Monday, 04'th Jan 2021
NEW YORK and LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Sumitovant Biopharma Ltd., the majority shareholder of Myovant Sciences (NYSE: MYOV), announced today that Myovant Sciences, a healthcare compa
